DRDO Invites EoI To Transfer Tech Of 2-DG Drug For Bulk Production

The DRDO created 2-Deoxy-D-Glucose (2-DG) has solicited Expression of Interest for the technology to be licensed to Indian pharmaceutical businesses for production. The drug was developed by a DRDO lab- the Institute of Nuclear Medicine and Allied Sciences in collaboration with Dr. Reddy Laboratories. Helping COVID patients for a faster recovery, the drug reduces dependency on medical oxygen. Notably, a higher number of patients treated with 2-DG reported RT-PCR negative.